It was reported that MSAs (e.g., paclitaxel) treatment can induce phosphorylation of Bcl-2 in prostate cancer cells and other cancer cells that express Bcl-2, leading to cell apoptosis [103,104]. This evidence concerns the gene BCL2 and prostate carcinoma.